Two year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat‐PAD, the first in a new class of synthetic peptide immuno‐regulatory epitopes

Abstract

Treatment with Cat-PAD (also known as ToleroMune® Cat, the first in a new class of synthetic peptide immuno-regulatory epitopes), in an Environmental Exposure Chamber (EEC) model of cat allergy showed a persistent treatment effect one year [1] and two years [2] after administration of only 4 injections over 12 weeks. Here we report the differences in Total Nasal Symptom Scores (TNSS) between Cat-PAD treatment arms and placebo two years after treatment started.